Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

  • PDAU and senior Boots managers meet to discuss ongoing dispute

    Talks have been held between members of the Pharmacists’ Defence Association Union (PDAU) and senior managers from Boots as part of an ongoing dispute over the legal status of the Boots Pharmacists’ Association (BPA).

    The meeting, which took place on 1 December 2017, is the latest development in a five-year battle by six Boots pharmacists to derecognise the BPA and secure independent representation at work through gaining collective bargaining rights for the PDAU.

    Last month, the Central Arbitration Committee (CAC), which resolves workplace disputes, accepted a legal application by the group of pharmacists to dissolve the BPA, triggering a 20-day statutory negotiating period. 

    Mark Pitt, assistant general secretary of the PDAU, which is representing the six pharmacists, said three options were on the table. The first, that Boots terminates its agreement with the BPA to allow the PDAU to formally apply for recognition, the second that the six applicants withdraw their application and the third that no agreement is reached.

    If no agreement is reached by the 13 December deadline, a final decision will be made by secret ballot.

    Pitt said: “Friday’s meeting was constructive but there was little concrete progress as we are still in the negotiating period.”

    He confirmed a meeting would also take place with the BPA as part of the ongoing negotiations.

  • pause slideshow

Elderly man taking a glucose test

Scottish Parliament to discuss prevention of type 2 diabetes

A one-off evidence session on the prevention of type 2 diabetes, organised by the Scottish Parliament’s Health and Sport Committee, will be held on 19 December 2017

UK business secretary Greg Clark

Investment from across the globe for UK life sciences 'sector deal'

The government has announced commitments and investment in the UK by 25 global organisations as part of its life sciences “sector deal”

EMA logo on building in Canary Wharf London

EMA starts safety referral for prostate cancer drug

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee has begun two new safety-related referrals

nigel-clarke-chair-GPhC

GPhC hits the ‘go’ button on revalidation

The General Pharmaceutical Council has formally approved the framework for revalidation and agreed a timetable for its implementation

Queen and Prince Philip

Queen's Anniversary Prize for university pharmacology department and institute of cancer research

Pharmacologists at the University of Liverpool’s department of molecular and clinical pharmacology have been awarded a Queen’s Anniversary Prize in recognition of their work to improve the safety and effectiveness of medicines.

Container Cargo for Import/Export

Brexit could hinder medicines supply to UK, MPs told

Medicines could become more difficult to import into the UK post-Brexit, MP members of the Health Select Committee were told on 5 December 2017

pharmacy supplying naloxone for harm reduction

FIP sets out how pharmacists can help cut harm from drugs of abuse

The International Pharmaceutical Federation has called for pharmacy organisations to engage with policymakers and health authorities to ensure more pharmacist involvement in drug harm reduction services

All News

brexit uk eu flags westminster ss 17

'No deal' Brexit would cause 'extensive problems' for the NHS, says Nuffield Trust

A ‘no deal’ Brexit would do serious damage to an already overstretched NHS, the Nuffield Trust has cautioned

ken-jarrold-chairman-government rebalancing board

Rebalancing Board will discuss supervision at its next meeting

Supervision within pharmacies is expected to be discussed early next year, the Rebalancing Medicines Legislation and Pharmacy Regulation Programme Board has announced.

All United Kingdom

Cannabinoid oil extract

Lack of evidence into paediatric cannabinoid useSubscription

The researchers found the strongest evidence of cannabinoid benefit in chemotherapy-induced nausea and vomiting, and in epilepsy

Psilocybin, magic mushroom

Magic mushrooms as a treatment for depression Subscription

Study sheds light on magic mushrooms’ mechanism in the brain in depression

Close up of a senior woman's mouth

Older adults at risk of medication-related dry mouthSubscription

In a meta-analysis of 26 studies, researchers found that medication use was significantly associated with dry mouth

Diabetes test close up

Statin therapy in obese patients and the risk of diabetesSubscription

Study highlights importance of people at high risk of diabetes being monitored during statin therapy

Insulin pump on young girl

Insulin pumps lead to better clinical outcomes compared with injection Subscription

Observational study compared rates of severe hypoglycaemia in diabetes patients using insulin pump and injection therapy.

Ultrasound of baby

Multivitamins during pregnancy could lower risk of some types of autismSubscription

Maternal multivitamin use with or without additional iron or folic acid was associated with lower odds of autism spectrum disorder with intellectual disability in the child.

Hepatitis C virions micrograph

Reducing hepatitis C virus transmissionSubscription

Combined needle provision and opioid substitution therapy could cut hepatitis C virus transmission risk.

Cancer drugs in preparation for chemotherapy

Lack of evidence that cancer drugs approved by the EMA improve survivalSubscription

BMJ published a study investigating the effectiveness of 48 drugs approved by the European Medicines Agency.

All Science

Special report

World AIDS Day: the long battle against the HIV epidemic

Great progress has been made in many countries to tackle the HIV epidemic. A newly diagnosed patient with access to the latest antiretroviral therapy (ART) can hope to have a normal life expectancy. Yet, over 30 years since the emergence of the virus, and 29 years since the first World’s AIDS Day, much more needs to done to bring these advances to developing countries and to reach groups at high risk of HIV transmission. One of the biggest barriers to achieving this aim is the stigma that is still rife in many countries.

Read more

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.